<DOC>
	<DOCNO>NCT00501943</DOCNO>
	<brief_summary>This double blind , randomize , parallel group design placebo-controlled mono-center study . Patients evaluate within twelve month CIS onset . Patients least 2 silent ovoid T2 bright area deep white matter clinic brain MRI scan offer participation study . Patients randomized oral riluzole placebo ( 1:1 ) . Patient take 50 mg riluzole placebo day one month . If 50 mg day well tolerate , patient go 50 mg twice daily rest study . They start Avonex ( Interferon beta 1a ) therapy 30 mcg IM weekly 3 month study drug ( riluzole placebo ) initiate liver function remain normal . Forty patient within twelve month onset CIS onset enrol UCSF MS Center . Patients evaluate every month first 12 month every three month thereafter total study duration 24-month . Enrollment period last six month .</brief_summary>
	<brief_title>Neuroprotection With Riluzole Patients With Early Multiple Sclerosis</brief_title>
	<detailed_description>To determine effect riluzole 50 mg bid MRI parameter , include T1 lesion load , atrophy gray white matter , 1H-MRSI ; determine safety riluzole administer orally 50 mg bid 2 year double blind clinical trial patient clinically isolate syndrome ( CIS ) least 2 silent T2-bright area deep white matter . These patient high risk conversion MS within 2 year faster rate atrophy ( Dalton 2004 ) . Specific aim : 1 . To determine effect treatment compare placebo annual change measure normalize brain gray white matter volume change . 2 . To determine effect riluzole compare placebo annual change proton spectroscopic intensities N-acetyl aspartate ( NAA ) glutamate normal appear white matter ( NAWM ) , acute chronic lesion . 3 . To determine safety riluzole 50 mg bid patient CIS association Avonex ( Interferon beta 1a ) 30 mcg IM week . 4 . To monitor change MS functional composite ( MSFC ) ( Cutter 1999 , Rudick 1998 ) , optic coherence tomography ( OCT ) , low contrast sensitivity EDSS patient . 5 . To monitor recovery exacerbation .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Riluzole</mesh_term>
	<criteria>1 . Patient must give write informed consent ; 2 . Patients early MS clinically isolate syndrome ( CIS ) past 12 month define acute subacute episode suggestive demyelination affect optic nerve , brain stem spinal cord central nervous system location . 3 . Entry age 1855 4 . Males females 5 . At least 2 silent T2 bright area deep white matter screen brain MRI . 6 . No riluzole , interferon , copaxone , cyclophosphamide , mitoxantrone offlabel immunosuppressive drug MS prior study entry 7 . No corticosteroid 4 week prior baseline MRI exam 8 . No prior exposure total lymphoid irradiation 9 . No history substance abuse , include document alcohol dependence within 6 month prior screen alcohol liver damage AST , ALT &gt; twice upper normal limit 10 . No pregnant nursing patient 11 . No history systemic illness medical condition would limit likelihood complete gadoliniumenhanced MRI procedure . Automatic exclusionary condition include hypersensitivity reaction riluzole tablet component , uncontrolled hypertension , epilepsy , insulin dependent diabetes , asthma , know malignancy skin cancer , symptomatic cardiac disease metallic object inside body . 12 . Patients willing use birth control study . 13 . Patients willing go Avonex therapy 3 month randomize study drug contraindication use interferon therapy . 1 . A history major depression psychosis . 2 . A clinically significant MS exacerbation within 30 day screen 3 . Pregnancy 4 . Abnormal screen liver function ( AST ALT &gt; twice upper normal limit ) . 5 . Patients receive hepatotoxic medication drug interfere CYP 1A2 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>